Crispr Therapeutics shares tumble after significant earnings miss
Peter Allan Davis, a director at Steven Madden , Ltd. (NASDAQ:SHOO), has sold 933 shares of the company’s common stock. The transaction, executed on March 11, 2025, was completed at a price of $26.976 per share, amounting to a total sale value of $25,168. The sale comes as the stock trades near its 52-week low of $27.98, with InvestingPro analysis indicating the company is currently undervalued. Following this transaction, Davis holds 6,824 shares of Steven Madden, Ltd. The sale was reported in a recent SEC filing, highlighting Davis’s continued involvement as a director with the company. Despite recent market pressure, Steven Madden maintains strong fundamentals with a healthy 41% gross margin and has sustained dividend payments for eight consecutive years. InvestingPro subscribers can access detailed analysis and 12 additional exclusive insights about SHOO’s market position and future prospects through the comprehensive Pro Research Report.
In other recent news, Steven Madden reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of $0.55, slightly above the forecasted $0.54. The company’s revenue also exceeded projections, reaching $582.3 million against the anticipated $550.64 million. Looking ahead, Steven Madden forecasts a 17-19% revenue increase for 2025, bolstered by the strategic acquisition of Kurt Geiger, a British footwear and accessories retailer. Despite these positive results, analysts have expressed concerns over potential challenges, including tariff impacts and gross margin pressures.
Telsey Advisory Group adjusted its price target for Steven Madden shares, lowering it to $38 from the previous $44, while maintaining a Market Perform rating. The firm’s analysis highlighted a mixed performance for the fiscal year 2024, with increased promotions and reliance on private label products impacting gross margins. Jefferies also revised its price target for Steven Madden, reducing it to $36 from $46, while keeping a Hold rating. The revision followed the company’s financial results, which showed stronger sales growth but softer gross margins.
Despite the anticipated $0.10 EPS accretion from the Kurt Geiger deal, Steven Madden’s EPS forecast for FY25 fell short of consensus estimates. Analysts remain cautious about the company’s profitability outlook amid a challenging macroeconomic environment. Investors will continue to monitor Steven Madden’s performance, particularly in light of the company’s strategic moves and the broader retail environment’s challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.